South African pharmaceutical firm iDexis is fighting back against local healthcare regulators over its Compounded GLP-1 Weight-Loss Injections. The company strongly defends its product safety amid serious compliance allegations.
The dispute follows a joint statement by the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC). The regulators ordered an immediate recall of the company’s semaglutide and tirzepatide products. Pharmaceutical companies originally developed these medicines to treat diabetes. However, they have become highly popular global weight-loss treatments.
Regulators Order Recall Of Compounded GLP-1 Weight-Loss Injections
A joint investigation by SAHPRA and the SAPC uncovered what they termed “serious deficiencies”. The regulatory bodies flagged issues with quality, safety, and compliance processes.
Regulators alleged that iDexis illegally imported active pharmaceutical ingredients (APIs). They also raised concerns about inadequate sterile manufacturing conditions at the facilities.
Furthermore, authorities claimed that iDexis operated outside the legal framework for compounding medicine. South African law limits compounding to individual patient prescriptions. Regulators alleged that iDexis instead manufactured and marketed these GIP/GLP-1-based products for broader commercial distribution.
IDexis Mounts Legal Defence For Compounded GLP-1 Weight-Loss Injections
The managing director of iDexis, Ruaan Louw, rejected all regulatory allegations. The company maintains that its operations are entirely safe and legal.
Louw highlighted an independent evaluation of the company’s compounding areas. This independent assessment concluded that iDexis complies with all statutory and regulatory requirements.
In an official letter sent to medical practitioners, iDexis stated it sources APIs from reputable international manufacturers. The company clarified that independent laboratories test these ingredients for sterility. Louw guaranteed the quality and safety of both semaglutide and tirzepatide formulations.
To support its stance, iDexis revealed it has supplied these products to 214,406 patients. The company claims patients have reported zero adverse reactions. However, iDexis did not publicly name its API sources or the testing laboratories.
Legal Constraints And Pharmaceutical Industry Response
The ongoing legal battle has limited public comments from both sides. Louw declined to answer detailed questions due to the pending litigation. He noted that the matter is currently sub judice.
Despite the silence, iDexis firmly maintains its processes align with the Medicines Act. It claims adherence to SAHPRA’s good compounding guidelines and SAPC’s good pharmacy guidelines.
Meanwhile, the SAPC issued a stern warning to frontline healthcare workers. Pharmacists and support staff who continue to dispense the recalled items face disciplinary action. This could include permanent removal from the official pharmacy register.
The Pharmaceutical Task Group, an industry umbrella body, heavily criticised iDexis’s response. Task group chair Stavros Nicolaou warned that manufacturing lapses pose a severe risk to patients. He emphasised that substandard and counterfeit GLP-1 products remain a massive concern for the sector.
Read the Original Article (May require a subscription)